THERAPEUTIC MODALITIES Archives - Page 7 of 22

Highly Selective Novel Heme Oxygenase-1 Hits Found by DEL

The heme oxygenase (HO) family comprises the major isozymes HO-1 and HO-2, of which HO-1 is deemed as an emerging...

Discovery of Potent, Selective, and Orally Available IRE1 alpha Inhibitors

Inositol-requiring enzyme 1α (IRE1α) is a sensor protein that plays a key role in multiple myeloma (MM) and is a...

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors

SARS-CoV-2 antivirals which have been clinically approved or are in late-stage development are directed against either the RNA-dependent RNA polymerase...

Research Strategies for the Discovery of Targeted Protein Degraders

In this webinar, experts present research strategies for the discovery of targeted protein degraders. Over the past decade, targeted protein degradation...

Pharmacodynamic and Pharmacokinetic Profile of a Novel GLP-1 Receptor Biased Agonist

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However,...

USP7 Inhibitors Reveal a Differentiated Mechanism of p53-Driven Anti-Cancer Activity

Ubiquitin-speciﬁc protease 7 (USP7) is a deubiquitinating enzyme that cleaves ubiquitin from a range of substrates, shielding them from degradation...

CRBN Structural Biology Services

Targeted protein degradation of disease-causing proteins by the E3 ligase cereblon (CRBN) represents a new therapeutic strategy for addressing challenging-to-treat...

mRNA-Encoded Modulators Suppress Tumor Growth

Unlike conventional protein-targeted therapies, nucleic acid therapeutics have the potential for long-lasting effects and greater target specificity. WuXi AppTec provides...

Recent Advances in HTE and Flow Chemistry

High throughput experimentation (HTE) is frequently employed to identify reaction conditions for challenging transformations, giving access to a diverse array...

Knowledge Library